WO 2005/077959 PCT/US2005/003247

What is claimed is:

1. A compound of formula (I)

5 wherein,

10

15

20

25

A is S, O, N, or CH;

B is S, O, N, or CH;

 R^1 and R^2 are the same or are different and are C_{1-8} alkyl, C_{2-8} alkylene, C_{3-8} cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C_{3-6} cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF_3 , SCF_3 , $NHC(O)_nR^5$, $S(O)_mR^5$, $S(O)_2NR^5R^6$, $C(S)NR^5R^6$, $C(O)_nR^5$;

n is 0, 1 or 2;

m is 0, 1 or 2;

R⁵ is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C₁₋₈alkoxy, aryl, heteroaryl, halogen, NO₂, CN, N₃, SCF₃, and CF₃;

 R^6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8} alkoxy, aryl, heteroaryl, halogen, NO_2 , CN, N_3 , SCF_3 , and CF_3 , or when R^1 and/or R^2 contains $S(O)_2NR^5R^6$, $CONR^5R^6$, or $C(S)NR^5R^6$, then R^5R^6 together with the nitrogen may form a heterocyclic ring; or

a pharmaceutically acceptable salt or solvate thereof.

WO 2005/077959 PCT/US2005/003247

2. A compound of claim 1 wherein in formula (I) R^1 and R^2 are independently a C_{1-6} alkyl, C_{3-6} cycloalkyl, or C_{1-6} alkylaryl as defined within and A is S and B is N.

- 5 3. A compound of claim 1 wherein in formula (I) R^1 is a C_{3-6} cycloalkyl and R^2 is an C_{1-6} alkyl as defined herein and A is S and B is N.
- 4. A compound of claim 1 which is

 3-amino-5,7-dibutylisothiazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, and

 3-amino-7-butyl-5-cyclopentylisothiazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione;

 or
 - a pharmaceutically acceptable salt thereof.
 - 5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in admixture with a pharmaceutically acceptable excipient.
- 15 6. A method for the prophylaxis of or for treating osteoporosis in a mammal comprising administering a effective amount of a compound of formula (I) according to claim 1 either neat or in admixture with a pharmaceutically acceptable excipient.